When they need a proven partner for levodopa
CONSIDER XADAGO NEXT
When they need a proven
partner for levodopa
CONSIDER XADAGO NEXT
Not actual patient. Used for
Why XADAGO now?
Levodopa has limitations over time
Despite its efficacy, the therapeutic window
of levodopa narrows over time1,2
Inconsistent levodopa response increases the need for adjunctive treatment options3
Mechanism of Action
XADAGO is a highly selective inhibitor of monoamine oxidase B (MAO-B)4,5
- XADAGO has over 1000-fold greater selectivity for MAO-B over MAO-A4
- The precise mechanism by which XADAGO exerts its effects in Parkinson’s disease (PD) is unknown4
Identifying XADAGO patients
These profiles represent patients who may be appropriate for treatment with XADAGO.
Michael, 57-year-old male, shop owner
First noticed right-hand tremor at age 55 and was diagnosed with PD a year later. He was initially started on a dopamine agonist but did not tolerate due to side effects—sometimes he would feel dizzy or more tired. He tolerated the change to carbidopa/levodopa 25/100 mg three times a day with good response.
About 1 year after starting carbidopa/levodopa, patient notes increased slowness, rigidity, and tremor with the current dose of carbidopa/levodopa. The symptoms are interfering with his work around the shop.
Celia, 62-year-old female, part-time accountant
Diagnosed with PD 4 years ago, Celia had improved motor function with carbidopa/levodopa (25 mg/100 mg) three times a day and pramipexole extended release 2.25 mg.
Now she is experiencing her carbidopa/levodopa dose wearing off sooner than previously. About 30-45 minutes before each dose, she notes increased tremor and balance difficulty. She is unable to increase her pramipexole due to lower-extremity edema at higher doses. The off time impairs her work as a part-time accountant.
1. Hickey P, Stacy M. Available and emerging treatments for Parkinson’s disease: a review. Drug Des Devel Ther. 2011(5):241-254. 2. Jankovic J. Motor fluctuations and dyskinesias in Parkinson’s disease: clinical manifestations. Mov Disord. 2005;20(Suppl 11):S11-S16. 3. Lewis SJ, Foltynie T, Blackwell AD, Robbins TW, Owen AM, Barker RA. Heterogeneity of Parkinson’s disease in the early clinical stages using a data driven approach. J Neurol Neurosurg Psychiatry. 2005;76(3):343-348. 4. XADAGO. Package Insert. US WorldMeds, LLC. 5. Onofrj M, Bonanni L, Thomas A. An expert opinion on safinamide in Parkinson’s disease. Expert Opin Investig Drugs. 2008;17(7):1115-1125.